182 related articles for article (PubMed ID: 28885232)
21. The value of phosphohistone H3 as a proliferation marker for evaluating invasive breast cancers: A comparative study with Ki67.
Kim JY; Jeong HS; Chung T; Kim M; Lee JH; Jung WH; Koo JS
Oncotarget; 2017 Sep; 8(39):65064-65076. PubMed ID: 29029412
[TBL] [Abstract][Full Text] [Related]
22. Using IHC to Predict Local Recurrence/Progression of DCIS: A Search for a More Cost-effective Solution.
Kilgore MR; Chang OH; Swanson PE; Schmidt RA; Garcia RL; Rendi MH
Breast J; 2016; 22(2):247-8. PubMed ID: 26696338
[No Abstract] [Full Text] [Related]
23. Paradoxical results obtained with Ki67-labeling and PHH3-mitosis index in glial tumors: a literature analysis.
Elmaci İ; Altinoz MA; Bolukbasi FH; Yapicier O; Sav A
Clin Neuropathol; 2017; 36(6):272-282. PubMed ID: 28853695
[TBL] [Abstract][Full Text] [Related]
24. Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
J Invest Dermatol; 2012 Apr; 132(4):1247-52. PubMed ID: 22297638
[TBL] [Abstract][Full Text] [Related]
25. Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas.
Duregon E; Bertero L; Pittaro A; Soffietti R; Rudà R; Trevisan M; Papotti M; Ventura L; Senetta R; Cassoni P
Oncotarget; 2016 Apr; 7(16):21190-8. PubMed ID: 27049832
[TBL] [Abstract][Full Text] [Related]
26. Mitotic Index Determined by Phosphohistone H3 Immunohistochemistry for Precise Grading in Follicular Lymphoma.
Bedekovics J; Irsai G; Hegyi K; Beke L; Krenács L; Gergely L; Méhes G
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):579-585. PubMed ID: 27997502
[TBL] [Abstract][Full Text] [Related]
27. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
[TBL] [Abstract][Full Text] [Related]
28. Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.
Duregon E; Cassenti A; Pittaro A; Ventura L; Senetta R; Rudà R; Cassoni P
Neuro Oncol; 2015 May; 17(5):663-9. PubMed ID: 25646026
[TBL] [Abstract][Full Text] [Related]
29. The Relationships between HER2 Overexpression and DCIS Characteristics.
Di Cesare P; Pavesi L; Villani L; Battaglia A; Da Prada GA; Riccardi A; Frascaroli M
Breast J; 2017 May; 23(3):307-314. PubMed ID: 27943525
[TBL] [Abstract][Full Text] [Related]
30. Phosphohistone H3 (PHH3) as a surrogate of mitotic figure count for grading in meningiomas: a comparison of PHH3 (S10) versus PHH3 (S28) antibodies.
Puripat N; Loharamtaweethong K
Virchows Arch; 2019 Jan; 474(1):87-96. PubMed ID: 30267302
[TBL] [Abstract][Full Text] [Related]
31. Phosphohistone H3 and Ki-67 labeling indices in cytologic specimens from well-differentiated neuroendocrine tumors of the gastrointestinal tract and pancreas: a comparative analysis using automated image cytometry.
Fung AD; Cohen C; Kavuri S; Lawson D; Gao X; Reid MD
Acta Cytol; 2013; 57(5):501-8. PubMed ID: 24021213
[TBL] [Abstract][Full Text] [Related]
32. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
[TBL] [Abstract][Full Text] [Related]
33. Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3.
Tracht J; Zhang K; Peker D
J Histochem Cytochem; 2017 Jul; 65(7):399-405. PubMed ID: 28651471
[TBL] [Abstract][Full Text] [Related]
34. The value of Phosphohistone H3 as a cell proliferation marker in oral squamous cell carcinoma. A comparative study with Ki-67 and the mitotic activity index.
Tancredi-Cueto N; Vigil-Bastitta G; Bologna-Molina R; Beovide-Cortegoso V
Med Oral Patol Oral Cir Bucal; 2022 Sep; 27(5):e444-e451. PubMed ID: 35975799
[TBL] [Abstract][Full Text] [Related]
35. Predicting short-term recurrence in pituitary adenomas: Phosphohistone-H3 (Ser 10) proves an effective biomarker.
Li C; Wei L; Li L; Wang J; Li R; Zhang Q; Zhou D
Clin Neuropathol; 2020; 39(2):70-79. PubMed ID: 31724532
[TBL] [Abstract][Full Text] [Related]
36. Phosphohistone H3 expression correlates with manual mitotic counts and aids in identification of "hot spots" in fibroepithelial tumors of the breast.
Ginter PS; Shin SJ; Liu Y; Chen Z; D'Alfonso TM
Hum Pathol; 2016 Mar; 49():90-8. PubMed ID: 26826415
[TBL] [Abstract][Full Text] [Related]
37. Phosphohistone-H3 and Ki-67 immunostaining in cutaneous pilar leiomyoma and leiomyosarcoma (atypical intradermal smooth muscle neoplasm).
Idriss MH; Kazlouskaya V; Malhotra S; Andres C; Elston DM
J Cutan Pathol; 2013 Jun; 40(6):557-63. PubMed ID: 23550775
[TBL] [Abstract][Full Text] [Related]
38. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
[TBL] [Abstract][Full Text] [Related]
39. A useful immunohistochemical approach to evaluate intraductal proliferative lesions of the breast and to predict their prognosis.
Omi Y; Yamamoto T; Okamoto T; Obara T; Kobayashi M
Histol Histopathol; 2011 Jan; 26(1):79-86. PubMed ID: 21117029
[TBL] [Abstract][Full Text] [Related]
40. Phosphohistone-H3 Proliferation Index Is Superior to Mitotic Index and MIB-1 Expression as a Predictor of Recurrence in Human Meningiomas.
Winther TL; Arnli MB; Salvesen Ø; Torp SH
Am J Clin Pathol; 2016 Oct; 146(4):510-20. PubMed ID: 27686177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]